Thyrocare Technologies Beheer
Beheer criteriumcontroles 1/4
De CEO Thyrocare Technologies is Rahul Guha, benoemd in May2022, heeft een ambtstermijn van 4.08 jaar. De totale jaarlijkse vergoeding van { bedraagt ₹ 61.06M, bestaande uit 75.3% salaris en 24.7% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.11% van de aandelen van het bedrijf, ter waarde ₹ 92.93M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 0.9 jaar en 2.9 jaar.
Belangrijke informatie
Rahul Guha
Algemeen directeur
₹61.1m
Totale compensatie
| Percentage CEO-salaris | 75.34% |
| Dienstverband CEO | 4.1yrs |
| Eigendom CEO | 0.1% |
| Management gemiddelde ambtstermijn | less than a year |
| Gemiddelde ambtstermijn bestuur | 2.9yrs |
Recente managementupdates
Recent updates
Narratiefupdate • Jun 04
539871: Expanded Healthcare Objects Clause Will Support Bullish Medium Term View
Analysts have maintained their fair value estimate for Thyrocare Technologies at ₹600, with unchanged assumptions on discount rate, revenue growth, profit margin and future P/E. This indicates that the latest review did not alter their fundamental valuation framework for the stock.Narratiefupdate • May 18
539871: Expanded Healthcare Mandate Will Support Bullish Medium Term View
Analysts have lifted their price target on Thyrocare Technologies from ₹571.67 to ₹600.00, and point to updated assumptions around revenue growth, profit margins and a slightly lower future P/E multiple as key drivers of the change. What's in the News The Board has approved changes to the Memorandum of Association to align it with the Companies Act, 2013, including updated references and clauses linked to current regulations (Key Developments).Narratiefupdate • Apr 28
539871: Stable Return Assumptions Will Support Bullish Medium Term View
Analysts have kept Thyrocare Technologies' fair value estimate steady at ₹571.67 per share, with only small tweaks to inputs such as expected revenue growth, profit margin, and future P/E assumptions driving this unchanged price target. Valuation Changes Fair Value: Kept unchanged at ₹571.67 per share, indicating no net impact from the latest input updates.Narratiefupdate • Apr 09
539871: Stable Assumptions And Upcoming Results Will Support Bullish View
Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, citing largely unchanged assumptions around fair value, discount rate, revenue growth, profit margin, and future P/E in their latest update. What's in the News A board meeting is scheduled on January 28, 2026 to consider and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Narratiefupdate • Mar 25
539871: Stable Assumptions And Upcoming Results Will Support Bullish Outlook
Analysts have kept their price target for Thyrocare Technologies broadly unchanged at around ₹572. This reflects stable assumptions on discount rate, revenue growth, profit margin and future P/E in their valuation work.Narratiefupdate • Mar 11
539871: Steady Assumptions And Upcoming Results Will Support Future Returns
Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, reflecting largely unchanged views on fair value, discount rate, growth and profit assumptions. What's in the News Board meeting scheduled for January 28, 2026, to review and consider the unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (company filing).Narratiefupdate • Feb 24
539871: Steady Assumptions And Upcoming Results Will Support Future Returns
Analysts have kept their price target for Thyrocare Technologies steady at ₹571.67, reflecting unchanged assumptions on fair value, discount rate, revenue growth, profit margins and future P/E in their updated work. What's in the News A board meeting is scheduled for January 28, 2026, to consider and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).Narratiefupdate • Feb 10
539871: Capitalisation Flexibility And Updated Profit Assumptions Will Support Returns
Analysts have slightly revised their price target on Thyrocare Technologies to ₹571.67, reflecting updated assumptions around discount rate, revenue growth, profit margin and future P/E that are now modestly lower than previously assumed. What's in the News Board meeting scheduled on January 28, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Narratiefupdate • Jan 26
539871: Capitalisation Flexibility And Higher Future P/E Will Support Returns
Analysts have nudged their fair value estimate for Thyrocare Technologies higher from ₹560.56 to ₹571.67, reflecting updated views on its long term revenue growth, profit margins and future P/E assumptions. What's in the News A board meeting is scheduled on January 28, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (company filing).Narratiefupdate • Jan 10
539871: Stock Split And Bonus Share Flexibility Will Support Future Returns
Analysts have lifted their fair value estimate for Thyrocare Technologies from ₹506.67 to ₹560.56, reflecting updated assumptions around revenue growth, profit margins and a higher future P/E multiple. What's in the News Board approval has been sought via a postal ballot dated October 14, 2025 to increase authorised share capital to INR 3,000,000,000, split into 300,000,000 equity shares of INR 10 each, with related changes to the Memorandum and Articles of Association (company filing).Narratiefupdate • Dec 26
539871: Stock Split And Bonus Capacity Will Drive Future Shareholder Returns
Analysts have maintained their price target for Thyrocare Technologies at ₹506.67 per share, reflecting unchanged assumptions on discount rate, revenue growth, profit margins, and future valuation multiples. What's in the News The board approved a proposal to increase authorised share capital and amend the Memorandum of Association and Articles of Association, subject to shareholder approval (Board Meeting, October 14, 2025, Key Developments).Narratiefupdate • Dec 11
539871: Bonus Share And Stock Split Plan Will Drive Future Shareholder Value
Analysts have sharply reduced their price target on Thyrocare Technologies to approximately ₹507 from about ₹1,520. This reflects a recalibrated fair value framework even as underlying assumptions for growth, margins, discount rate and future valuation multiples remain largely unchanged.Narratiefupdate • Nov 27
539871: Upcoming Board Approvals And Dividend Proposals Will Shape Shareholder Value
Analysts have maintained their fair value estimate for Thyrocare Technologies at ₹1,520 per share, citing stable outlooks in revenue growth and profit margins as the key drivers behind the unchanged price target. What's in the News The board meeting on October 14, 2025 considered and approved unaudited financial results for the quarter and half year ended September 30, 2025.Narratiefupdate • Nov 12
539871: Upcoming Board Decisions And Shareholder Actions Will Influence Outlook
Analysts have maintained their price target for Thyrocare Technologies at ₹1,520, citing stable expectations for revenue growth, profit margin, and valuation metrics. What's in the News Special or Extraordinary Shareholders Meeting scheduled for November 16, 2025, to be conducted via postal ballot in India (Key Developments).Narratiefupdate • Oct 29
Upcoming Bonus Shares And Dividend Proposal Will Drive Shareholder Value
Analysts have maintained their price target for Thyrocare Technologies at ₹1,520, citing stable revenue growth projections along with only minor adjustments in profit margin and future valuation metrics. What's in the News The board meeting was held on October 14, 2025 to approve unaudited financial results, consider the declaration of an interim dividend, and review a proposal for the issue of bonus shares (Board Meeting).Narratiefupdate • Oct 15
Franchise Expansion And PharmEasy Partnerships Will Secure Future Success
Analysts have raised their fair value estimate for Thyrocare Technologies from ₹1,355 to ₹1,520. They cite improved profit margins and expectations of sustainable earnings, even though revenue growth is moderating.Narratiefupdate • Sep 05
Franchise Expansion And PharmEasy Partnerships Will Secure Future Success
With both Net Profit Margin and Future P/E ratio remaining stable, analysts have kept Thyrocare Technologies’ fair value unchanged at ₹1355. What's in the News Special/Extraordinary Shareholders Meeting scheduled via postal ballot in India.
Nieuw narratief • Jan 26
Integrating Vimta Labs And Achieving 100% NABL Accreditation Will Position The Company As An Industry Leader
Expanding geographical presence and strategic acquisitions are expected to drive future revenue growth and enhance service offerings.Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Mar 31 2026 | ₹61m | ₹46m | ₹2b |
| Dec 31 2025 | n/a | n/a | ₹1b |
| Sep 30 2025 | n/a | n/a | ₹1b |
| Jun 30 2025 | n/a | n/a | ₹1b |
| Mar 31 2025 | ₹56m | ₹42m | ₹915m |
| Dec 31 2024 | n/a | n/a | ₹877m |
| Sep 30 2024 | n/a | n/a | ₹840m |
| Jun 30 2024 | n/a | n/a | ₹776m |
| Mar 31 2024 | ₹35m | ₹14m | ₹708m |
| Dec 31 2023 | n/a | n/a | ₹655m |
| Sep 30 2023 | n/a | n/a | ₹648m |
| Jun 30 2023 | n/a | n/a | ₹599m |
| Mar 31 2023 | ₹32m | n/a | ₹645m |
Compensatie versus markt: De totale vergoeding ($USD 641.57K ) Rahul } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Indian markt ($USD 394.69K ).
Compensatie versus inkomsten: De vergoeding van Rahul is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Rahul Guha (48 yo)
4.1yrs
Tenure
₹61,055,380
Compensatie
Mr. Rahul Franklin Guha served as President of Operations at API Holdings Limited since 2024 and serves as its Managing Director and Chief Executive Officer since August 27, 2025 and its Director since Aug...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD, CEO & Chairman | 4.1yrs | ₹61.06m | 0.11% ₹ 92.9m | |
| Chief Financial Officer | less than a year | ₹6.62m | geen gegevens | |
| Company Secretary & Compliance Officer | 1.4yrs | ₹4.22m | geen gegevens | |
| Chief Operating Officer | less than a year | geen gegevens | geen gegevens | |
| Head of Strategy & Investor Relations | no data | geen gegevens | geen gegevens | |
| Chief Commercial Officer | less than a year | geen gegevens | geen gegevens | |
| Vice President | no data | ₹5.33m | geen gegevens | |
| Strategy Manager | no data | geen gegevens | geen gegevens | |
| Vice President of Lab Operations & Quality | no data | geen gegevens | geen gegevens | |
| Strategy Manager | no data | geen gegevens | geen gegevens |
0.9yrs
Gemiddelde duur
43yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van 539871 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 0.9 jaar), wat duidt op een nieuw team.
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| MD, CEO & Chairman | 4.1yrs | ₹61.06m | 0.11% ₹ 92.9m | |
| Non-Executive Independent Director | 8.8yrs | ₹550.00k | geen gegevens | |
| Independent Director | 2.9yrs | ₹900.00k | geen gegevens | |
| Non-Executive Independent Director | 2.9yrs | ₹300.00k | geen gegevens | |
| Additional Non-Executive & Non-Independent Director | less than a year | ₹5.32m | geen gegevens | |
| Independent Director | 2yrs | ₹500.00k | geen gegevens | |
| Independent Director | 2yrs | ₹500.00k | geen gegevens |
2.9yrs
Gemiddelde duur
46yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van 539871 wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.9 jaar), wat duidt op een nieuw bestuur.
Bedrijfsanalyse en status van financiële gegevens
| Gegevens | Laatst bijgewerkt (UTC-tijd) |
|---|---|
| Bedrijfsanalyse | 2026/06/07 08:17 |
| Aandelenkoers aan het einde van de dag | 2026/06/05 00:00 |
| Inkomsten | 2026/03/31 |
| Jaarlijkse inkomsten | 2026/03/31 |
Gegevensbronnen
De gegevens die gebruikt zijn in onze bedrijfsanalyse zijn afkomstig van S&P Global Market Intelligence LLC. De volgende gegevens worden gebruikt in ons analysemodel om dit rapport te genereren. De gegevens zijn genormaliseerd, waardoor er een vertraging kan optreden voordat de bron beschikbaar is.
| Pakket | Gegevens | Tijdframe | Voorbeeld Amerikaanse bron * |
|---|---|---|---|
| Financiële gegevens bedrijf | 10 jaar |
| |
| Consensus schattingen analisten | +3 jaar |
|
|
| Marktprijzen | 30 jaar |
| |
| Eigendom | 10 jaar |
| |
| Beheer | 10 jaar |
| |
| Belangrijkste ontwikkelingen | 10 jaar |
|
* Voorbeeld voor effecten uit de VS, voor niet-Amerikaanse effecten worden gelijkwaardige formulieren en bronnen gebruikt.
Tenzij anders vermeld zijn alle financiële gegevens gebaseerd op een jaarperiode, maar worden ze elk kwartaal bijgewerkt. Dit staat bekend als Trailing Twelve Month (TTM) of Last Twelve Month (LTM) gegevens. Meer informatie.
Analysemodel en Snowflake
Details van het analysemodel dat is gebruikt om dit rapport te genereren zijn beschikbaar op onze Github-pagina. We hebben ook handleidingen over hoe je onze rapporten kunt gebruiken en tutorials op YouTube.
Leer meer over het team van wereldklasse dat het Simply Wall St-analysemodel heeft ontworpen en gebouwd.
Industrie en sector
Onze industrie- en sectormetrics worden elke 6 uur berekend door Simply Wall St, details van ons proces zijn beschikbaar op Github.
Bronnen van analisten
Thyrocare Technologies Limited wordt gevolgd door 12 analisten. 4 van deze analisten hebben de schattingen van de omzet of winst ingediend die zijn gebruikt als input voor ons rapport. Inzendingen van analisten worden de hele dag door bijgewerkt.
| Analist | Instelling |
|---|---|
| Alka Katiyar | 360 ONE Capital Market Private Limited |
| Rahul Agarwal | CGS International |
| Kameswari V. S. Chavali | FirstCall Research |